SUPERNUS PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $206.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2026-08-03
- 2026-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $206.00K.
- 2026-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $206.00K.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $31.26M.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $11.45M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2026-06-30 | $206.00K 10-Q · filed 2026-08-03 |
| 2026-03-31 | $206.00K 10-Q · filed 2026-05-05 |
| 2025-12-31 | $31.26M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $11.45M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-03 |
| 2025-03-31 | $30.00M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $47.34M 10-Q · filed 2026-08-03 |
| 2024-09-30 | $46.98M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $48.00M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $52.35M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $53.45M 10-K · filed 2026-03-02 |
| 2023-09-30 | $53.65M 10-Q · filed 2024-11-04 |
| 2023-06-30 | $54.11M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $53.32M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $54.97M 10-K · filed 2026-03-02 |
| 2022-09-30 | $57.37M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $56.88M 10-Q · filed 2023-11-08 |
| 2022-03-31 | $56.14M 10-Q · filed 2023-11-08 |
| 2021-12-31 | $80.48M 10-K · filed 2025-02-25 |
| 2021-09-30 | $69.05M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $68.97M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $77.72M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $76.70M 10-K · filed 2022-04-13 |
| 2020-06-09 | $115.70M 10-Q · filed 2021-11-05 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |